A putative therapeutic target in sickle cell disease: Q9H165

Ablatotech Signals reports today on a putative therapeutic target — Q9H165 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in sickle cell disease.

Background

The putative target Q9H165, also known as a candidate protein associated with sickle cell disease (SCD), has emerged from a comprehensive analysis of gene expression data. This candidate protein has been identified through expression-profiling studies, suggesting a potential role in the pathophysiology of SCD. However, it is noteworthy that there are currently no registered Phase 1 or higher clinical programs targeting this protein, indicating an opportunity for further exploration in the context of therapeutic development.

Data-mining rationale

The identification of Q9H165 as a putative target was achieved by cross-referencing UniProt's reviewed human entries related to "sickle cell disease" against 39 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). This systematic approach allowed for the identification of gene expression patterns that may be relevant to SCD, highlighting Q9H165 as a notable candidate for further investigation.

Why prior analyses may have missed this

Many of the GEO datasets utilized in this analysis predate the adoption of modern empirical-Bayes statistical methods, such as limma, which are essential for robust differential expression analysis. The lack of proper multiple-testing correction in earlier studies may have led to the oversight of significant expression changes associated with Q9H165. Therefore, a re-analysis of these datasets using contemporary statistical techniques could yield new insights into the role of this candidate in sickle cell disease.

Reasoning for further validation

To substantiate the potential relevance of Q9H165 in sickle cell disease, the following experimental approaches are suggested: 1. Re-analyze the matched GEO datasets using limma with a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to identify differentially expressed genes with greater accuracy. 2. Validate the top differentially expressed genes, including Q9H165, through quantitative PCR (qPCR) in an independent cohort to confirm expression patterns. 3. Investigate tissue specificity of Q9H165 by utilizing resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its expression across various tissues. 4. Employ pathway analysis tools like STRING and OmniPath to explore the biological pathways in which Q9H165 may be involved, providing context for its potential role in SCD. 5. If validation is achieved, assess the druggability of Q9H165 using databases such as DGIdb and ChEMBL to explore potential therapeutic avenues.

References